Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Generex Biotechnology Corp. (GNBTQ) Message Board

From another Board: Zolisonkel (04/11/2019):

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36566
(Total Views: 400)
Posted On: 11/05/2019 8:35:53 AM
Posted By: luisGenerex
From another Board:

Zolisonkel (04/11/2019):

"It is truely unbelievable what is currently going on here, in this message board, as well as with the PPS at the OTC exchange.
All people, who are wondering what is going on, this is only smoke and mirrors.
Let me remind everyone on the facts and what is fundamentally happening at GNBT:
In my view, the PPS will soon be in double digits, and these crooks, who are currently driving the pps down and/or are bashing GNBT on this message board, know this very well, and thus are trying everything they can to steal your shares. So do not be fooled:
Ok, here is a list of the most important facts:
1) This stock is extremely undervalued right now. Just look at the fact that is traded at ~$2.5/share before the company retired about 20M or 1/3 of their outstanding shares and the OTC officials did not automatically adjust the PPS by roughly 50%. After that retirement of shares, the stock should have traded at ~$3.7/share
2) Next 10-K is expected every day now, which should show significantly increased revenues and profits. The first 10-K after JoeM took over, which shoes an equity positive balance sheet. This is typically a really big deal for investors.
3) Uplisting is around the corner, which by itself should much more visibility to much larger audience and potential investors. A lot of folks would never invest in an OTC company, but they would in a company with GNBT's future potentials, if only it would be listed on a national exchange, such as Nasdaq. CEO stated clearly that he still positive that this is going to be realised within the next 4 weeks (until the end Nov.2019).
4) Once uplisting is achieved, significantly improved financing opportunities will be available to GNBT and Joe has clearly stated that he has 2 major acquisition (clasically financed via loans) in the pipeline, ready to be executed, which he will close immediately after GNBT being listed on Nasdaq.
5) NGIO spin-out.There is a SEVERAL 100 Million USD value HIDDEN from the common public right now, in all the ongoing developments of Antigen Express, which will be the major part of NGIO, which GNBT plans to spin-out until the end of Nov., which in turn will make this significant value visible and GNBT plans on keeping at least a controlling 51% interest in NGIO, which should boost the market cap. of GNBT as well. Just look at numbers, the entire market cap of GNBT (which currently includes 100% of NGIO) is 44M*$1.30/share ~57M USD. NGIO alone is estimated to have a value in access of 300M. So from the value of NGIO alone, GNBT should have a current PPS of ~$4.5/share.
6) The Excellagen product line that they are currently just starting to fully put to market.
7) The MSO business, which GNBT has already restructured and will continue to expand once propper financing options are available.
8) clinical trials of the breast cancer vaccine as well as the Oral-lyn (syringe free, buccal tissue delivered insulin).
9) The entire business that they are getting into about the partnership with the Arizona diabetes excelence center and that in combination with their soon to be acquisition of 51% of AltuCell which has a well advanced development of a cure for Type 1 diabetes.
10) .... that is by for not all that GNBT has on its agenda, and most of it still has the status of "recently acquired" or "soon to be acquired", which means as well that the full potential is by far not realised. So the future looks extremely bright ahead in my view. We just have to sit back and wait for everything to unfold. $10/share is, in my view, just a first start. If you give this a little more time, than just the next couple of months, I think we will all laugh our asses off about $10/share"


(2)
(0)




Generex Biotechnology Corp. (GNBTQ) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us